Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Lowered by UBS Group

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by UBS Group from a “buy” rating to a “neutral” rating in a research note issued on Thursday, Marketbeat Ratings reports. They presently have a $738.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $1,130.00. UBS Group’s price target indicates a potential upside of 8.28% from the company’s previous close.

A number of other research analysts also recently issued reports on the stock. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Evercore ISI reduced their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Cantor Fitzgerald reissued a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Barclays decreased their price objective on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Finally, Leerink Partnrs cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $1,015.38.

Regeneron Pharmaceuticals Trading Down 1.7 %

REGN stock opened at $681.58 on Thursday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a twelve month low of $666.25 and a twelve month high of $1,211.20. The company has a market cap of $74.90 billion, a P/E ratio of 16.87, a PEG ratio of 1.60 and a beta of 0.10. The business has a fifty day moving average of $741.54 and a 200-day moving average of $952.59.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. International Assets Investment Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after acquiring an additional 879,916 shares in the last quarter. Worldquant Millennium Advisors LLC bought a new position in Regeneron Pharmaceuticals in the third quarter valued at $127,489,000. Icon Wealth Advisors LLC increased its stake in Regeneron Pharmaceuticals by 18,342.0% in the 3rd quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock valued at $79,874,000 after buying an additional 75,569 shares during the last quarter. State Street Corp lifted its position in Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after buying an additional 61,277 shares in the last quarter. Finally, Epoch Investment Partners Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 57.7% in the 2nd quarter. Epoch Investment Partners Inc. now owns 163,296 shares of the biopharmaceutical company’s stock valued at $171,629,000 after acquiring an additional 59,745 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.